Recent Updates
Recently added Catalysts
VIR Positive Sentiment

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

Wednesday, October 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vir Biotechnology has entered into a collaboration and license agreement with Gilead Sciences to develop three novel PRO-XTEN® dual-masked T-cell engagers aimed at solid tumors. Gilead will have exclusive rights to commercialize these TCE candidates, leveraging Vir's expertise in TCE discovery and protein engineering. This partnership is expected to advance cancer treatment options significantly.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration with Gilead enhances research capabilities.
  • Focus on novel T-cell engagers could lead to innovative cancer treatments.
  • Exclusive licensing agreement may boost financial prospects.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
9.5%
average across 6 past catalysts
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis

Full Press Release Details

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens. Gilead will have an exclusive license to develop and commercialize the novel TCEs. Through this collaboration, Vir Biotechnology will apply its deep expertise in TCE discovery and protein engineering, its pr

Frequently Asked Questions

What is the focus of the collaboration between Vir and Gilead?

The collaboration aims to discover and develop novel PRO-XTEN® dual-masked T-cell engagers for solid tumors.

What rights does Gilead have in this agreement?

Gilead has an exclusive license to develop and commercialize the novel T-cell engagers.

What expertise does Vir bring to the collaboration?

Vir Biotechnology contributes its expertise in T-cell engager discovery and protein engineering.

How many T-cell engager candidates are being developed?

Three novel PRO-XTEN® T-cell engager candidates are being developed through this collaboration.

ShareAdd on Google
Tags: VIR Vir Biotechnology Gilead Sciences T-cell engagers solid tumors PRO-XTEN
Last updated: Oct 14, 2026

Biotech snapshot

Cash runway
$529M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TobevibartPhase 3
Viral Hepatitis →

Catalyst track record

+85%
best trade around VIR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VIR.

See every catalyst's timing & PoA →